Asthma Chronic Clinical Trial
Official title:
Use of Aptar Digital Health's Respiratory Disease Management Platform for Asthma: A Pilot Study
The United Kingdom has a high prevalence of asthma (over 12%) and some of the worst health outcomes in Europe. The management of respiratory disease and associated patient outcomes has long been an area of focus and improvement for the National Health Service. With the advancement of digital health technology, there is the potential to transform patient care and improve outcomes. The Aptar Digital Health respiratory disease management platform, a digital therapeutic will be utilized to determine its value and how it supports: i) asthma patient engagement and facilitates communication between patients and providers to accelerate medication adherence; ii) asthma control through the use of the Asthma Control Questionnaire-5. In addition, spirometry and fractioned exhaled nitric oxide will be utilized during the study to validate and enhance current National Institute for Health and Care Excellence guidelines.
Status | Not yet recruiting |
Enrollment | 118 |
Est. completion date | November 2025 |
Est. primary completion date | May 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 16 Years and older |
Eligibility | Inclusion Criteria: - Age = 16 years - Utilization of asthma controller therapy: inhaled corticosteroids (ICS), long-acting ß2-agonists (LABAs) and/or fixed combination therapies of LABA and ICS (medium to high-dose ICS/LABA therapy) - Use of metered dose inhaler (MDI) and / or dry powder dose inhaler (DPI) list of compatible medications is noted in section 9.2. - FeNO = 45 ppb - Primary respiratory diagnosis of asthma - Patients with uncontrolled, moderate-to-severe asthma - Non-smoker - Capable of giving signed informed consent, which includes compliance with requirements and restrictions listed in consent form and protocol. - Subject understands and is willing, able, and likely to comply with study procedures and restrictions - Willingness to participate in this study and to use the Aptar Digital Health technology - Willingness to share information / data with Aptar Digital Health (through informed consent) Access to technology - Access to a smartphone (requirements Android =13 and iOS =16 - Ability to use smartphone (smartphone usability assessment to be provided by Aptar Digital Health) - Access to a current email account - Access to data / Wi-Fi Exclusion Criteria: - Age < 16 years - FeNO < 45 ppb - Known or suspected alcohol or drug abuse which in opinion of investigator could interfere with subject's proper completion of the protocol requirement - History of life-threatening asthma: Defined as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures within last 6 months - A lower respiratory tract infection within 7 days of the screening visit - Concurrent diagnosis of chronic obstructive pulmonary disease (COPD) or other respiratory disorders including active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases. - History of hypersensitivity/intolerance to any components of the study inhalers (example, lactose, magnesium stearate). In addition, subjects with a history of severe milk protein allergy that, in the opinion of the study physician, contraindicates participation will also be excluded. - Ever received treatment with biological based therapy example, omalizumab, mepolizumab, for asthma. - Received an investigational drug and/or medical device within 30 days of entry into this study (Screening), or within five drug half-lives of the investigational drug, whichever is longer - An immediate family member of the participating investigator, sub-investigator, study coordinator, employee of the participating investigator, or any family member of a Aptar Pharma, Aptar Digital Health, Voluntis, or Cohero employee. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
CoheroHealth | Aptar Digital Health, Lindus Health |
Barnes CB, Ulrik CS. Asthma and adherence to inhaled corticosteroids: current status and future perspectives. Respir Care. 2015 Mar;60(3):455-68. doi: 10.4187/respcare.03200. Epub 2014 Aug 12. — View Citation
Barry LE, O'Neill C, Butler C, Chaudhuri R, Heaney LG. Cost-Effectiveness of Fractional Exhaled Nitric Oxide Suppression Testing as an Adherence Screening Tool Among Patients With Difficult-to-Control Asthma. J Allergy Clin Immunol Pract. 2023 Jun;11(6):1 — View Citation
Blakey JD, Bender BG, Dima AL, Weinman J, Safioti G, Costello RW. Digital technologies and adherence in respiratory diseases: the road ahead. Eur Respir J. 2018 Nov 22;52(5):1801147. doi: 10.1183/13993003.01147-2018. Print 2018 Nov. — View Citation
Boinet T, Leroy-David C. [Asthma in adults]. Actual Pharm. 2021 Feb;60(603):13-17. doi: 10.1016/j.actpha.2020.12.008. Epub 2021 Feb 22. French. — View Citation
Budhathoki P, Shrestha DB, Rawal E, Khadka S. Corticosteroids in COVID-19: Is it Rational? A Systematic Review and Meta-Analysis. SN Compr Clin Med. 2020;2(12):2600-2620. doi: 10.1007/s42399-020-00515-6. Epub 2020 Oct 19. — View Citation
Busse WW, Kraft M. Current unmet needs and potential solutions to uncontrolled asthma. Eur Respir Rev. 2022 Jan 25;31(163):210176. doi: 10.1183/16000617.0176-2021. Print 2022 Mar 31. — View Citation
Chan A, De Simoni A, Wileman V, Holliday L, Newby CJ, Chisari C, Ali S, Zhu N, Padakanti P, Pinprachanan V, Ting V, Griffiths CJ. Digital interventions to improve adherence to maintenance medication in asthma. Cochrane Database Syst Rev. 2022 Jun 13;6(6): — View Citation
George M, Bender B. New insights to improve treatment adherence in asthma and COPD. Patient Prefer Adherence. 2019 Jul 31;13:1325-1334. doi: 10.2147/PPA.S209532. eCollection 2019. — View Citation
Jackson DJ, Busby J, Pfeffer PE, Menzies-Gow A, Brown T, Gore R, Doherty M, Mansur AH, Message S, Niven R, Patel M, Heaney LG; UK Severe Asthma Registry. Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era. — View Citation
Lara M, Edelen MO, Eberhart NK, Stucky BD, Sherbourne CD. Development and validation of the RAND Asthma Control Measure. Eur Respir J. 2014 Nov;44(5):1243-52. doi: 10.1183/09031936.00051614. Epub 2014 Jul 17. — View Citation
McDonald VM, Yorke J. Adherence in severe asthma: time to get it right. Eur Respir J. 2017 Dec 21;50(6):1702191. doi: 10.1183/13993003.02191-2017. Print 2017 Dec. No abstract available. — View Citation
Merchant R, Szefler SJ, Bender BG, Tuffli M, Barrett MA, Gondalia R, Kaye L, Van Sickle D, Stempel DA. Impact of a digital health intervention on asthma resource utilization. World Allergy Organ J. 2018 Dec 3;11(1):28. doi: 10.1186/s40413-018-0209-0. eCol — View Citation
Nordon C, Grimaldi-Bensouda L, Pribil C, Nachbaur G, Amzal B, Thabut G, Marthan R, Aubier M; COBRA Study Group. Clinical and economic burden of severe asthma: A French cohort study. Respir Med. 2018 Nov;144:42-49. doi: 10.1016/j.rmed.2018.10.002. Epub 201 — View Citation
Rudin RS, Fanta CH, Qureshi N, Duffy E, Edelen MO, Dalal AK, Bates DW. A Clinically Integrated mHealth App and Practice Model for Collecting Patient-Reported Outcomes between Visits for Asthma Patients: Implementation and Feasibility. Appl Clin Inform. 20 — View Citation
Sherbourne CD, Stucky BD, Edelen MO, Eberhart NK, Kleerup E, Lara M. Assessing the validity of the RAND negative impact of asthma on quality of life short forms. J Allergy Clin Immunol. 2014 Oct;134(4):900-7. doi: 10.1016/j.jaci.2014.03.002. Epub 2014 Apr — View Citation
* Note: There are 15 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Step-up from inhaled corticosteroids to biologics | Some patients with severe asthma may require stronger medication, known as biologics, which are injectables. The thought is that if adherence and technique to a patient's controller inhaled corticosteroid can be improved, there could be a subset of severe patients who do not require escalation to biologics.
The higher the percentage of severe asthmatic patients who are escalated to biologics, the worse. The lower the percentage of severe asthmatic patients who are escalated to biologics, the better. Change in biologic escalation percentage between baseline, 6-months, and prior published evidence that indicates biologic escalation percentage for those with severe asthma. Change in biologic escalation cost will be determined by multiplying the biologic percentage escalation between baseline, 6-months, and prior published evidence by the cost per biologic treatment. Cost values will derived either from NHS costing database or published evidence. |
6 months | |
Other | Asthma related oral corticosteroids utilization and associated cost | Some patients with asthma who have an exacerbation may require oral corticosteroids. If adherence and technique to a patient's controller inhaled corticosteroid can be improved, there could be less exacerbations and thus, less utilization of oral corticosteroids.
The higher the percentage of asthmatic patients who are prescribed oral corticosteroids, the worse. The lower the percentage of asthmatic patients who are prescribed oral corticosteroids, the better. Change in oral corticosteroid usage for those with asthma will be noted in the 1-year prior to baseline and then from study start to the end of the study. Change in oral corticosteroid cost will be determined by multiplying the number of oral corticosteroid doses between 1-year prior to baseline and then from study start to 6-months, by the cost of an oral corticosteroid dose. Cost values will derived either from the NHS costing database or published evidence. |
6 months | |
Other | Asthma related accident and emergency department visits and associated cost | Some asthma severe exacerbations may require an accident and emergency department visit. If adherence and technique to a patient's controller inhaled corticosteroid can be improved, there could be less exacerbations and thus, less accident and emergency department visits.
The higher the number of accident and emergency department visits, the worse. The lower the number of accident and emergency department visits, the better. Change in accident and emergency department visits will be noted in the 1-year prior to baseline and then from study start to 6-months, the end of the study. Change in accident and emergency cost will be determined by multiplying the number of accident and emergency department visits between 1-year prior to baseline and then from study start to 6-months by the cost of an accident and emergency department visit. Cost values will derived either from the NHS costing database or published evidence. |
6 months | |
Other | Asthma related unscheduled outpatient clinic visits and associated cost | Some patients may have unscheduled outpatient clinic visits due to worsening asthma symptoms or exacerbations. If adherence and technique to controller inhaled corticosteroid is improved, there could be less worsening of symptoms and exacerbations and a decrease in unscheduled outpatient clinic visits.
The higher the number of unscheduled outpatient clinic visits, the worse. The lower the number of unscheduled outpatient clinic visits, the better. Change in unscheduled outpatient clinic visits will be noted in the 1-year prior to baseline and then from study start to 6-months, the end of the study. Change in unscheduled outpatient clinic visit cost will be determined by multiplying the number of unscheduled outpatient clinics visits between 1-year prior to baseline and then from study start to 6-months by the cost of an unscheduled outpatient clinic visit. Cost values will derived either from the NHS costing database or published evidence. |
6 months | |
Other | Asthma related inpatient hospitalization, associated length of stay, and associated cost | Some patients may have asthma related inpatient hospitalizations due to worsening asthma symptoms or exacerbations. If adherence and technique to controller inhaled corticosteroid is improved, there could be less worsening of symptoms and exacerbations and a decrease in inpatient hospitalizations.
The higher the number of inpatient hospitalizations, the worse. The lower the number of inpatient hospitalizations, the better. Change in inpatient hospitalizations will be noted in the 1-year prior to baseline and then from study start to 6-months, the end of the study. Change in inpatient hospitalization cost will be determined by multiplying the number of asthma related inpatient hospitalizations between 1-year prior to baseline and then from study start to 6-months by the cost of an inpatient hospitalization. Cost values will derived either from the NHS costing database or published evidence. |
6 months | |
Other | Computer System Usability Questionnaire | The Computer System Usability Questionnaire is a validated questionnaire that is used in digital health to obtain feedback on the usefulness, ease of use, and satisfaction of digital platform.
There are 19 questions in the Computer System Usability Questionnaire. Each question has a range between 1 and 7 with 1 = strongly disagree and 7 = strongly agree. For each question, there is an option for not applicable (NA). The higher the mean score, the better. The lower the mean score, the worse. The Computer System Usability Questionnaire will be administered to all patients at the end of the study. |
6 months | |
Other | Semi-structured interviews using the 2019 Rudin et al study | The study by Rudin, R.S., Fanta, C.H., Qureshi, N., Duffy, E., Edelen, M.O., Dalal, A.K., Bates, D.W. (2019). A clinically integrated mHealth app and practice model for collecting patient-reported outcomes between visits for asthma patients: implementation and feasibility. App Clin Inform, 10, 783-793 - contains a validated semi-structured interview used to obtain for feedback on the feasibility, acceptability, and use of digital health technologies. Interviews can be administered to patients and health care providers. There are 7 questions for patients. There are 5 questions for health care providers. There is no score as this is a qualitative survey.
Interviews will be conducted either in-person or virtually by the clinical research organization, Lindus Health. At the conclusion of the interviews, Lindus Health will then use thematic analysis will be used to determine the main themes. |
6 months | |
Primary | Asthma Control Questionnaire - 5 scores | Asthma Control Questionnaire - 5 has 5 questions each ranging from a low of 0 to a high of 6. 0 indicates "never" and 6 indicates "always". The minimum mean score is a 0 and the highest mean score is a 6. The lower the score the better the outcome.
Change in normal distribution and mean Asthma Control Questionnaire - 5 scores from baseline to 6 months, which is the end of the study. |
6 months | |
Secondary | Mini-Asthma Quality of Life Questionnaire | Mini-Asthma Quality of Life Questionnaire has 15 questions each ranging from a low of 1 to a high of 7. 1 indicates "all the time" and 7 indicates "none of the time". The higher the mean score the better the outcome.
Change in normal distribution and mean values of Mini-Asthma Quality of Life Questionnaire scores from baseline to 6-months, which is the end of study. |
6 months | |
Secondary | Rescue medication usage | Asthmatics are prescribed two medications: 1) controller; 2) rescue. The controller medication schedule is prescribed by the healthcare provider. Rescue medication is used on an "as needed" basis when an asthmatic needs immediate relief due to an exacerbation.
The lower the use of rescue medication, the better. The higher the use of rescue medication, the worse. Change in normal distribution and mean values of rescue medication usage (calculated on a daily and per patient basis) from baseline to 6-months, which is the end of study. |
6 months | |
Secondary | Inhaled corticosteroid steroid daily adherence | Asthmatics are prescribed two medications: 1) controller inhaled corticosteroid; 2) rescue. The controller inhaled corticosteroid steroid schedule is prescribed by the healthcare provider and is usually scheduled to be taken on a daily basis. If a patient is supposed to take their controller inhaled corticosteroid medication twice in one day and takes it twice, their adherence to their controller inhaled corticosteroid would be 100% on that day. If the patient is supposed to take it twice, but only takes it once, then their adherence to their controller inhaled corticosteroid would be 50% on that particular day.
The higher the adherence the better the outcome. The lower the adherence the worse the outcome. Change in normal distribution and mean values of controller inhaled corticosteroids adherence from baseline to 6-months, which is the end of study. |
6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04438408 -
National Survey on Care Pathway and Quality of Life in Patients With Severe Asthma According to Their Phenotype.
|
||
Recruiting |
NCT04693975 -
Social Distancing During the COVID-19 Pandemic and People Living With Chronic Respiratory Diseases
|
||
Completed |
NCT04456270 -
Asthma Control in a Dutch Primary Care Population
|
||
Active, not recruiting |
NCT04593394 -
Inducible Laryngeal Obstruction in Severe Asthma in Severe Asthma
|
||
Not yet recruiting |
NCT03879590 -
Efficacy Of Doxophylline As A Sparing Treatment For Inhaled Corticosteroids In Mexican Children With Asthma
|
Phase 3 | |
Recruiting |
NCT04613245 -
Health-Related Quality of Life of Patients With Asthma During the Pandemic of COVID-19
|
||
Withdrawn |
NCT05304494 -
Sentinel - Triaging Acute Breathlessness Using Multi-Modal Biomarkers
|
||
Completed |
NCT03498742 -
Asthmatic Subjects Could Live Without Short Acting beta2 Agonists
|
||
Recruiting |
NCT05572177 -
Feasibility of a Smartphone Application for Asthma Self-management
|
N/A | |
Not yet recruiting |
NCT05841901 -
Huang-long Zhi-xiao Granule Improves the Control Rate of Chronic Persistent of Asthma
|
N/A | |
Not yet recruiting |
NCT04799678 -
Pilot Voice Sample Collection From People With Asthma
|
||
Not yet recruiting |
NCT06273072 -
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
|
Phase 2 | |
Terminated |
NCT03736629 -
Azithromycin Treatment for the Airway Microbiome in Asthma
|
Phase 2 | |
Recruiting |
NCT03788057 -
Inflammatory Indices in Predicting the Failure of Inhaled Corticosteroids Reduction in Young Participants With Asthma
|
N/A | |
Not yet recruiting |
NCT02283008 -
Inhaler Technique Training
|
N/A | |
Completed |
NCT02227394 -
Study to Compare the Effects of Z7200 And Symbicort® Turbohaler on Respiratory Imaging Parameters in Asthmatic Patients
|
Phase 2 | |
Not yet recruiting |
NCT05432440 -
Evaluation of Pharmacist-guided Digital-based Asthma Education for Indonesian Children With Asthma
|
N/A | |
Completed |
NCT05270278 -
Characteristics of Type 2- High Inflammatory Endotype of Asthma Using New Biomarkers From Peripheral Blood and Exhaled Air and Its Effect on the Outcome of Therapy
|
||
Completed |
NCT03642418 -
User-Friendly Spirometer and Mobile App for Self-Management and Home Monitoring of Asthma Patients
|
||
Recruiting |
NCT05609760 -
Pictograms to Facilitate Comprehension of Medical Indications
|
N/A |